Abstract
Neutrophils are key players in the hyperinflammatory response upon SARS-CoV-2 infection. We have previously described that cytosolic proliferating cell nuclear antigen (PCNA) controls neutrophil survival and NADPH oxidase-dependent ROS production. We here show that both PCNA and S100A8 expression and interaction were elevated in neutrophils from patients with COVID-19 compared to healthy donors and this was correlated with disease severity. Increased PCNA expression was accompanied by a decreased apoptosis and increased NADPH-oxidase activity in neutrophils from COVID-19 patients compared to healthy donors. These effects, as well as the interaction between PCNA and S100A8, were potently counteracted by T2 amino alcohol (T2AA), a PCNA inhibitor, demonstrating that the PCNA scaffold orchestrated neutrophil activation. Notably, the interaction between PCNA-S100A8 was more intense in the CD16high-CD62Llow activated neutrophil subset. We propose that PCNA-S100A8 complex acts as potential driver for neutrophil dysregulation in COVID-19 and show for the first time that the PCNA scaffold is a decisive component of both neutrophil activation and heterogeneity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Fondation pour la Recherche Medicale Grant EQU202003010155 (VWS) the Investissements Avenir programme ANR-11-IDEX-0005-02 Sorbonne Paris Cite LabEx INFLAMEX (VWS) the French National Research Agency (ANR) with the Grant RA-COVID-19 V5-COVINNATE (MHN) Grant DENDRISEPSIS ANR-17-CE15-0003 (FP) Grant APCOD ANR-17-CE15-0003-01 (FP) the Sao Paulo research Foundation Grant FAPESP-SCRIPPS 15/50387-4 (FS)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individuals hospitalized due to COVID-19 from April 2020 to January 2022 were recruited in Paris, at the Cochin Hospital from the Internal Medicine department (authorization #2019-3677), the Respiratory medicine department (authorization #2020 #A02700-39) and from the Intensive Care Medicine department (authorization #2018 #A01934-51) and at Bichat Hospital from the Intensive Care Medicine department (authorization #2020-715). This study was approved by the Hospital Ethics Committee, according to the Declaration of Helsinki. Each patient gave written informed consent
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.